<PAGE>

                                  FORM 10-QSB
                                AMENDMENT NO. 1

                      SECURITIES AND EXCHANGE COMMISSION
                            Washington, D.C. 20549

             [X] Quarterly Report Pursuant to Section 13 or 15(d)
                    of the Securities Exchange Act of 1934

                For the quarterly period ended June 30, 2000
                                               -------------

                                      OR

             [_] Transition Report Pursuant to Section 13 or 15(d)
                    of the Securities Exchange Act of 1934

       For the transition period from _______________ to _______________

                        Commission file number 0-21384
                                               -------

                          KAIRE HOLDINGS INCORPORATED
             ---------------------------------------------------
            (Exact name of registrant as specified in its charter)


          Delaware                                              13-3367421
-------------------------------                            -------------------
(State or other jurisdiction of                              (I.R.S. employer
incorporation or organization)                            identification number)

             7348 Bellaire, North Hollywood, California         91605
             --------------------------------------------------------
           (Address of principal executive offices)          (Zip Code)

      Registrant's Telephone number, including area code: (818) 255-4996
                                                          --------------

                  7348 Bellaire Ave. North Hollywood, California       90025
  --------------------------------------------------------------------------
 (former, name, address and former fiscal year, if changed since last report)

Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the Registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.    Yes  X    No
                                          ---

State the number of shares outstanding of each of the Registrant's classes of
common stock, as of the latest practicable date.

                                      Outstanding at
          Class of Common Stock       June 30, 2000
          ---------------------       ------------------
            $.001 par value           115,929,033 shares

        Transitional Small Business Disclosure Format  Yes ____  No  X
                                                                    ---
<PAGE>

                                  FORM 10-QSB
                      Securities and Exchange Commission
                            Washington, D.C. 20549

                          KAIRE HOLDINGS INCORPORATED

                                     Index

PART I - FINANCIAL INFORMATION

     Item 1. Consolidated Financial Statements

             Condensed Consolidated Balance Sheets at
               December 31, 1999 and June 30, 2000 (unaudited)

             Condensed Consolidated Statements of Operations
               for the three and six months ended June 30, 1999 (unaudited)
               and 2000 (unaudited)

             Condensed Consolidated Proforma Statements of Operations at
               December 31, 1999 and June 30, 2000 (unaudited)

             Condensed Consolidated Statements of Cash Flows
               for the six months ended June 30, 1999 (unaudited)
               and 2000 (unaudited)

             Kaire Holdings Incorporated and Classic Care Consolidated Proforma
               Statements of Operations At December 31, 1999 and June 30, 2000

             Notes to Condensed Consolidated Financial Statements

     Item 2.  Management's Discussion and Analysis of Financial Condition
                and Results of Operations.

PART II. - OTHER INFORMATION

     Item 1. Legal Proceedings
     Item 4. Submission of Matters of a Vote to Security Holders
     Item 5. Other Information
     Item 6. Exhibits and Reports on Form 8-K

SIGNATURES

                                      -2-
<PAGE>

                         PART I. FINANCIAL INFORMATION
                         -----------------------------

ITEM I. FINANCIAL STATEMENTS

                 KAIRE HOLDINGS INCORPORATED AND SUBSIDIARIES
                          CONSOLIDATED BALANCE SHEET
                      December 31, 1999 and June 30, 2000

                                    ASSETS
                                    ------


                                                 December 31,    June 30,
                                                    1999           2000
                                                 -----------   -----------
                                                               (unaudited)

 Current assets
     Cash and cash equivalents                   $  130,668   $  287,226
     Accounts receivables, net                       29,332      769,667
     Inventory                                                   315,973
     Prepaid expenses and other assets                            60,337
                                                 ----------   ----------

          Total current assets                      160,000    1,433,203

     Furniture and equipment, net                                252,866
     Other Assets                                                 52,387
     Deposits                                                      5,000
     Patents, net
     Investments                                                   5,000
     Goodwill, net                                             3,774,999

                                                 ----------   ----------
          Total assets                           $  160,000   $5,523,455
                                                 ----------   ----------


                     LIABILITIES AND SHAREHOLDERS' DEFICIT
                     -------------------------------------

Current liabilities
     Notes payable                                   25,000       25,000
     Accounts payable and accrued expenses          640,426    1,030,421
     Convertible notes payable and debentures        81,000      452,892
                                                 ----------   ----------

          Total current liabilities                 746,426    1,508,313

       Total liabilities                            746,426    1,508,313
                                                 ----------   ----------

  The accompanying notes are an integral part of these financial statements.

                                      -3-
<PAGE>

                 KAIRE HOLDINGS INCORPORATED AND SUBSIDIARIES
                          CONSOLIDATED BALANCE SHEET
                      December 31, 1999 and June 30, 2000



                                                    December 31,       June 30,
                                                       1999             2000
                                                    ------------    -----------
                                                                    (unaudited)

Shareholders' deficit
  Common stock, $0.001 par value
    authorized 400,000,000 shares,
    77,197,226 issued and outstanding
    and 115,929,033 issued and
    outstanding respectively.                            77,197        116,093

  Additional paid-in-capital                         30,521,658     35,621,262
  Accumulated deficit                               (31,185,281)   (31,722,213)
                                                   ------------   ------------

   Total Shareholders' Equity (Deficit)                (586,426)     4,015,142

Total liabilities and stockholders' deficit        $    160,000   $  5,523,455
                                                   ------------   ------------

  The accompanying notes are an integral part of these financial statements.

                                      -4-
<PAGE>

                  KAIRE HOLDINGS INCORPORATED AND SUBSIDARIES
                     CONSOLIDATED STATEMENTS OF OPERATIONS
           FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 1999 and 2000

<TABLE>
<CAPTION>
                                                 Three Months Ended                Six Months Ended
                                                      June 30,                          June 30,
                                                 ------------------              ---------------------
                                                 1999             2000           1999             2000
                                                 ----             ----           ----             ----
<S>                                          <C>              <C>           <C>            <C>
 REVENUES
    Products and Services                    $    67,324       727,785      $    136,413       788,844
     Lease Rentals                                     -             -                 -             -
                                                 -------       -------           -------       -------
     Total Revenue                                67,324       727,785           136,413       788,844

Cost of Revenues                                  13,453       464,914            20,707       495,984

Gross Profit                                      53,871       262,870           115,706       292,861

Operating Expenses
    Research and development
    Selling, general and administrative          192,062       352,491           321,932       587,943
                                             -----------   -----------       -----------   -----------
     Total Operating Expenses                    192,062       352,491           321,932       587,943

                                             -----------   -----------       -----------   -----------
Loss from Operations                            (138,191)     ( 89,620)         (206,226)     (295,082)

Other Income and (Expense)
Interest expense                                 (17,351)            -           (52,073)     ( 14,544)
Other Expenses                                         -       (50,000)                -      (235,000)
Below Market Note Conversion                    (235,493)            -          (235,493)
Other Income                                     399,118        11,829           399,118        11,829
                                             -----------   -----------       -----------   -----------
     Total interest expense and other            131,013       (38,171)           96,290      (237,715)

Loss before provision for state
                                                  (7,178)     (127,791)         (109,935)     (532,797)

Provision for state income taxes                                   400               400           800

Net Loss                                          (7,178)     (128,191)         (109,935)     (533,597)
                                             -----------   -----------       -----------   -----------

Basic Loss per Share                         $   (0.0004)  $   (0.0016)     $     (0.006)  $    (0.006)

Basic shares weighted average                 18,800,606    77,974,715        18,304,909    76,694,180

Diluted Loss per Share                       $   (0.0004)  $   (0.0016)     $     (0.006)  $   (0.0068)

Diluted shares weighted average               18,800,606    82,624,705        18,304,909    77,974,705
</TABLE>

          See the accompanying notes to these consolidated statements

                                      -5-
<PAGE>

                  KAIRE HOLDINGS INCORPORATED AND SUBSIDARIES
                     CONSOLIDATED STATEMENTS OF CASH FLOWS
                For the Six Months Ended June 30, 1999 and 2000

<TABLE>
<CAPTION>
                                                         (Unaudited)       (Unaudited)
                                                            1999              2000
                                                         -----------       -----------
<S>                                                    <C>                 <C>
Cash flows from operating activities
Net Loss                                               $  (109,935)        $  (533,597)
Adjustments to reconcile net loss to net cash
 used in operating activities:
    Deposits                                                                    (5,000)
    Amortization and Depreciation                           10,127              17,457
    Common stock issued for services                       171,604              94,500
    Common stock issued for interest on notes                4,529              14,543
    Common stock issued for Convertible notes                                   26,546
    Common stock issued for other compensation                                 240,000
    Convertible notes payable/debentures                                        10,000
    Compensation expenses related to below-market stock    235,493
     Options granted
    Non Cash Other expenses                                                    137,589
(Increase) decrease in:
    Accounts receivable                                     11,350            (740,335)
    Prepaid expenses and other assets                       (2,626)            (60,337)
    Inventories                                                               (315,973)
Increase (decrease) in:
    Accounts payable and accrued expenses                 (603,531)            761,887
                                                         ---------          ----------
      Net cash used in operating activities               (282,989)           (352,719)
                                                         ---------          ----------
Cash flows from investing activities
    Purchase of furniture and equipment                                       (254,528)
    Purchase of Goodwill                                                      (690,794)
    Investment in affiliates                                     -              (5,000)
                                                         ---------          ----------
      Net cash used in investing activities                                 (1,303,041)

Cash flows from financing activities
    Payments on notes payable
    Proceeds from issuance of common stock                 240,000           1,459,599
    Proceeds from issuance of convertible notes             75,000
                                                         ---------
      Net cash provided by financing activities            315,000           1,459,599
                                                         ---------          ----------
</TABLE>

  The accompanying notes are an integral part of these financial statements.

                                      -6-
<PAGE>

                  KAIRE HOLDINGS INCORPORATED AND SUBSIDARIES
                     CONSOLIDATED STATEMENTS OF CASH FLOWS
                For the Six Months Ended June 30, 1999 and 2000


                                                       (Unaudited)  (Unaudited)
                                                             1999         2000
                                                          -------     --------

          Net decrease in cash and cash equivalents        32,011      156,558
                                                          -------     --------

Cash and cash equivalents, beginning of period              6,331      130,668
                                                          -------     --------

Cash and cash equivalents, end of period                  $38,342     $287,226
                                                          -------     --------


   The accompanying notes are an integral part of these financial statements

                                      -7-
<PAGE>

                 KAIRE HOLDINGS INCORPORATED and CLASSIC CARE
                CONSOLIDATED PROFORMA STATEMENTS OF OPERATIONS
                    At December 31, 1999 and June 30, 2000


                                               (Unaudited)   (Unaudited)
                                                  1999          2000
                                               -----------   -----------

 REVENUES
      Products and Services                    $ 5,345,024   $ 2,891,827
                                               -----------   -----------
 Total Revenue                                   5,345,024     2,891,827

Cost of Revenues                                 3,385,387     2,082,499
                                               -----------   -----------

Gross Profit                                     1,959,637       809,328
                                               -----------   -----------

Operating Expenses
     Research and development                            0             0
     Selling, general and administrative         2,090,491     1,111,533
                                               -----------   -----------
       Total Operating Expenses                  2,090,491     1,111,533
                                               -----------   -----------

Loss from Operations                              (130,854)     (302,204)

Interest Income (Expense) and Other                              (14,544)
Amortization (Proforma)                           (189,540)      (94,770)
Interest expense - lease operations                      -             -
Other Expense                                                   (235,000)
Other Income                                             -        11,829
Net Losses on pending acquisition                        -
                                               -----------   -----------
    Total interest expense and other              (189,540)     (332,485)

Loss before provision for state                -----------   -----------
      income tax                                  (320,394)     (634,689)

Provision for state income taxes                       400           800

Net Loss                                       $  (320,794)  $  (635,489)
                                               -----------   -----------

  Basic Loss per Share                         $    (0.009)  $    (0.008)
  Diluted Loss per Share                       $    (0.006)  $    (0.008)

Weighted average shares outstanding Primary     51,751,627    76,694,180
Weighted average shares outstanding Diluted     75,486,485    77,974,705


   The accompanying notes are an integral part of these financial statements

                                      -8-
<PAGE>

                 KAIRE HOLDINGS INCORPORATED and SUBSIDIARIES
                  NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                  (unaudited)
                                 June 30, 2000

1.   Significant Risks
     -----------------

          The Company has incurred net losses of $1,037,608 and $472,537 for the
years ended December 31, 1998 and 1999, respectively and an additional loss of
$109,935 and $533,597 for the six months ended June 30, 1999 and June 30, 2000.

          The Company's condensed consolidated financial statements have been
prepared on the assumption the Company will continue as a going concern. The
Company however has suffered recurring losses from operations that raise doubt
about its ability to continue as a going concern. The financial statements do
not include any adjustments relating to the recoverability and classification of
asset carrying amounts or the amount of liabilities that might result should the
Company be unable to continue as a going concern. The Company's condensed
consolidated financial statements have been prepared on the assumption the
Company will continue as a going concern.

          The Company, formerly known as Interactive Medical Technologies Ltd.,
was incorporated in Delaware in 1986. The Company's former main business was
providing non-radioactive diagnostic products and laboratory analysis services
to private and government research facilities, academic centers, and hospitals
engaged in studying the effects of experimental drugs and/or surgical procedures
have on regional blood flow. These products and services are sold through the
Company's E-Z Trac division. As previously disclosed, effective May 1, 2000, the
Company had entered into an agreement with Stason Labs of Irvine, whereby the
laboratory was transferred to Stason's Irvine facility for the purpose of
providing better service to existing customers plus to explore the possibilities
of expanding the laboratory services into new areas.

          Kaire Holdings, Inc.'s current focus is in developing and marketing
products and services to businesses and consumers of specific market segments by
joining traditional business concepts ("brick and mortar") with internet
technologies. The e-commerce segment of the industry is highly volatile and
there is not guarantee that the Company will succeed.

          In 1999 the Company formed YesRx.com., which is an Internet drugstore
that is focused on pharmaceuticals, health, wellness and beauty products. The
site targets Internet shoppers and in particular, the senior citizen. In
addition to the Business to Consumer strategy, the company is in the process of
implementing a tightly focused Business to Business/Agency plan to fulfill
orders to various targeted groups through an advocate or enterprise that acts as
a central distributor. YesRx focuses on chronic care as opposed to emergency
needs. The company does not provide urgent care medications but works with the
patient who has regular medication needs and multiple refills. This provides
operational feasibility and recurring revenue streams. It is management's intent
to spin off YesRx.com into a separate company, contingent on funding.

                                      -9-
<PAGE>

        In furtherance of its internet initiatives, on June 1, 2000, the Company
acquired Classic Care Pharmacy, a Los Angeles-based business to business
pharmacy. Through this acquisition, Kaire will be able to expand its business to
business and consumer customer base. The purchase called for Kaire to pay
Classic Care ownership $1 million in cash in installments and up to 15.5 million
shares of restricted Kaire common stock.

        In 1993, the Company acquired Venus Management, Incorporated, ("VMI")
which was incorporated in New York on August 1, 1989. VMI's principle assets at
the time were two MRI systems, one was leased to an MRI service provider
operating in New York and the second unit which was not operational. The non-
operational unit was returned to the finance company upon which VMI received a
release of claims agreement. Concerning the leased system, on or about March 1,
1995, VMI entered into a transfer of interest agreement with Siemens Credit
Corp., Medical Funding of America ("MFA") and Tri-county whereby Kaire gave its
corporate guaranty for all of Venus' obligations under this agreement. MFA
defaulted on the loan and on April 2, 1997 Siemens Credit Corporation filed a
civil action against Kaire for the accelerated amount due plus costs.
Subsequently, a Transfer of Interest Agreement was drawn up between Venus
Management, Siemens Credit Corporation and Medical Management, Inc. (NYSE symbol
CMI) whereby CMI would take over the lease and at the same time the legal action
was put on hold. (see legal Proceedings).

        In December 1997 the Company entered into an agreement (the "Agreement")
to acquire 80% of Kaire International, Inc. ("KII"), a network marketing firm
based in Longmont, Colorado. In exchange for KII's Common Stock, the Agreement
called for the Company to invest an initial $1,000,000 plus Company Common
Stock, and to subsequently provide additional capital totaling $2,000,000 by the
latter of February 15, 1998 or the completion of KII's year-end audit. The
Company was unable to raise the funds reducing the Company ownership in KII to
24%. A write down of the KII investment was reflected in the Company's 1997
financial statements.

        On December 10, 1998, Natural Health Trends Corp., ("NHTC") (NASDAQ:
Symbol NHTCC), announced it had signed an agreement as of November 24, 1998 to
purchase certain assets of KII for a combination of Series E and Series F
Preferred stock, Acquisition Warrants and a percentage of NHTC's net income for
a period of five years. It is not known what effect the NHTC agreement will have
on Kaire Holding's investment in KII, thus due to the uncertainty in Kaire
Holding's ability to recover its investment in KII, its investment in KII was
written off for the year ending December 1997.

        On February 19, 1998, Kaire Holdings, Incorporated changed its name from
Interactive Medical Technologies, Ltd., changed its NASDAQ OTC BBS symbol to
"KAHI" and reverse split its Common Stock at a ratio of seventy-five (75) to one
(1).

        The Company carries no direct product liability insurance, relying
instead on the coverage afforded by its distributors and the manufacturers from
whom it obtains products. These coverages directly protect the insured that pay
the premiums and only secondarily the Company. There is no assurance that such
coverages will adequately cover any claims that may be brought against the
Company. In addition, the Company does not have any general liability coverage.

                                      -10-
<PAGE>

2.      Summary Significant Accounting Policies
        ---------------------------------------

             Basis of Presentation
             ---------------------

        The accompanying condensed consolidated financial statements have been
prepared assuming that the Company will continue as a going concern. Certain
matters raise substantial doubt about the Company's ability to continue as a
going concern. As discussed in Note 1, the Company operates under extreme
liquidity constraints and, because of recurring losses, increasing difficulty in
raising necessary additional capital. Management's plan in regard to these
matters is described above. The financial statements do not include any
adjustments relating to the recoverability and classification of asset carrying
amounts or the amount and classification of liabilities that might result should
the Company be unable to continue as a going concern.

        In the opinion of the management the accompanying consolidated financial
statements contain all adjustments necessary (consisting of only normal
recurring accruals) to present fairly the financial position at June 30, 2000,
the results of its operations for the three and six months ended June 30, 2000
and the cash flow for six months ended June 30, 2000. Certain information and
footnote disclosures normally included in financial statements that would have
been prepared in accordance with generally accepted accounting principles have
been condensed or omitted pursuant to the rules and regulations of the
Securities and Exchange Commission, although management of the Company believes
that the disclosures in these financial statements are adequate to make the
information presented therein not misleading. It is suggested that these
condensed financial statements and notes thereto be read in conjunction with the
financial statements and the notes thereto included in the Company's December
31, 1999 Form 10-KSB.

        The results of operations for the six months ended June 30, 2000 are not
necessarily indicative of the results of operations to be expected for the full
fiscal year ending December 31, 1999.

        Income Taxes
        ------------

        The Company utilizes SFAS No. 109, "Accounting for Income Taxes," which
requires the recognition of deferred tax assets and liabilities for the expected
future tax consequences of events that have been included in the financial
statements or tax returns. Under this method, deferred income taxes are
recognized for the tax consequences in future years of differences between the
tax bases of assets and liabilities and their financial reporting amounts at
each period end based on enacted tax laws and statutory tax rates applicable to
the periods in which the differences are expected to affect taxable income.
Valuation allowances are established, when necessary, to reduce deferred tax
assets to the amount expected to be realized. The provision for income taxes
represents the tax payable for the period and the change during the period in
deferred tax assets and liabilities.

                                      -11-
<PAGE>

        Fair Value of Financial Instruments
        -----------------------------------

        The Company measures its financial assets and liabilities in accordance
with generally accepted accounting principles. For certain of the Company's
financial instruments, including cash and cash equivalents and accounts payable
and accrued liabilities, the carrying amounts approximate fair value due to
their short maturities. The amounts shown for notes payable also approximate
fair value because current interest rates offered to the Company for debt of
similar maturities are substantially the same.

        Stock Split
        -----------

        On or about February 19, 1998, the Company effected a 1-for-75 reverse
stock split of its common stock. All share and per share data have been
retroactively restated to reflect this stock split.

        Stock Options
        -------------

        SFAS No. 123, "Accounting for Stock-Based Compensation," establishes and
encourages the use of the fair value based method of accounting for stock-based
compensation arrangements under which compensation cost is determined using the
fair value of stock-based compensation determined as of the date of grant and is
recognized over the periods in which the related services are rendered. The
statement also permits companies to elect to continue using the current implicit
value accounting method specified in Accounting Principles Bulletin ("APB")
Opinion No. 25, "Accounting for Stock Issued to Employees," to account for
stock-based compensation. The Company has elected to use the implicit value
based method and has disclosed the pro forma effect of using the fair value
based method to account for its stock-based compensation.

        Income taxes are provided for the tax effects of transactions reported
in the financial statements and consist of state income taxes currently due. No
federal income taxes are due as a result of the Company's net operating loss
carryforwards.

        Net Loss Per Share
        ------------------

        In 1997, the Financial Accounting Standard Board ("FASB") issued
Statement of Financial Accounting Standards ("SFAS") No. 128, "Earnings per
Share." SFAS No. 128 replaced the previously reported primary and fully diluted
earnings per share with basic and diluted earnings per share. Unlike primary
earnings per share, basic earnings per share excludes any dilutive effects of
options, warrants, and convertible securities. Diluted earnings per share is
very similar to the previously reported fully diluted earnings per share. Basic
earnings per share is computed using the weighted-average number of common
shares outstanding during the period. Common equivalent shares are excluded from
the computation if their effect is anti-dilutive.


   3.   Capital Transactions, Convertible Notes Payable and Debentures

                                      -12-
<PAGE>

        In December 1997 the Company entered into an agreement (the "Agreement")
to acquire 80% of Kaire International, Inc. ("KII"), a network marketing firm
based in Longmont, Colorado. In exchange for KII's Common Stock, the Agreement
called for the Company to invest an initial $1,000,000 plus Company Common
Stock, and to subsequently provide additional capital totaling $2,000,000 by the
latter of February 15, 1998 or the completion of KII's year-end audit. The
Company was unable to raise the funds reducing the Company ownership in KII to
24%. A write down of the KII investment was reflected in the Company's 1997
financial statements.

        On December 10, 1998, Natural Health Trends Corp., ("NHTC") (NASDAQ:
Symbol NHTCC), announced it had signed an agreement as of November 24, 1998 to
purchase certain assets of KII for a combination of Series E and Series F
Preferred stock, Acquisition Warrants and a percentage of NHTC's net income for
a period of five years. It is not known what effect the NHTC agreement will have
on Kaire Holding's investment in KII, thus due to the uncertainty in Kaire
Holding's ability to recover its investment in KII, its investment in KII was
written off for the year ending December 1997.

        During the fiscal year ended December 31, 1997, to raise capital, the
Company issued securities using the exceptions available under the Securities
Act of 1933 including unregistered sales made pursuant to Section 4(2) of the
Securities Act of 1933 and pursuant to Regulation S, as follows:

        For the period beginning on or about May 5, 1997 through December 31,
1997, there were 25,566,804 shares (340,891 shares on a post reverse split
basis) of common stock sold issued pursuant to Section 4(2) of the Securities
Act of 1933 and pursuant to Regulation S for approximately $1,222,639.

        For the period beginning May 23, 1997 through December 31, 1997,
$441,500 of convertible promissory notes were converted into 7,354,321 shares
(98,058 shares on a post reverse split basis) of common stock. The majority of
these shares were issued in reliance on Regulation S with the remainder made
pursuant to Section 4(2) of the Securities Act of 1933.

        1997 quarterly interest payments totaling $6,417.60 due on a convertible
promissory note held by the Wolas Family Trust were paid with 134,426 shares
(1,792 shares on a post reverse split basis) of the Company's common stock,
issued pursuant to Section 4(2) of the Securities Act of 1933.

        On December 18, 1997, 118,209,200 shares (1,576,123 shares on a post
reverse split basis) of the Company's common stock were issued to the
shareholders of Kaire International Inc., in exchange for at least 80% of Kaire
International's outstanding shares of common stock. The Company's common stock
were issued pursuant to Section 4(2) of the Securities Act of 1933.

        During October through December 1997, the Company issued 8% convertible
debentures due three years from the date of issuance. The debentures are
convertible beginning with the 41/st/ day after issuance and at a conversion
price equal to 70% of the average closing bid price of the Company's common
stock during the last five days prior to the conversion date. In connection with
the issuance of these debentures, the Company recorded additional interest
amounting to $364,000 related to the beneficial conversion feature of the
debentures. The note holders have certain registration rights. At

                                      -13-
<PAGE>

December 31, 1997, convertible debentures outstanding aggregated to $850,000.
These funds were issued to Kaire International Inc. As of December 31, 1998,
$225,000 remains to be converted.

        During the fiscal year ended December 31, 1998, the Company issued
securities using exemptions available under the Securities Act of 1933 including
sales made pursuant to Section 4(2) of the Securities Act of 1933 and pursuant
to Regulation S, as follows (please note that the below 1998 shares issued
reflect the 75 to 1 reverse split that occurred on February 19, 1998).

        For the period January 1, 1998 through December 31, 1998 there were
337,153 shares of common stock sold issued pursuant to pursuant to Regulation S
for approximately $43,552.

        For the period January 1, 1998 through December 31, 1998, $1,089,100 of
convertible promissory notes were converted into 11,066,292 shares of common
stock. The majority of these shares were issued in reliance on Regulation S and
pursuant to Section 5 of the Securities Act of 1933.

        During the fiscal year ended December 31, 1998, 1,394,138 registered
shares of common stock were issued for consulting services rendered.

        Certain 1998 quarterly interest payments through December 30, 1998
totaling $48,980 due on a convertible promissory note held by various note
holders were paid with 333,310 shares of the Company's common stock, issued
pursuant to Section 4(2) of the Securities Act of 1933.

        In February 1998, as a result of a Special Shareholder Meeting, the
Company effected a 1-for-75 reverse stock split of its common stock. All share
and per share data have been retroactively restated to reflect this stock split.

        As of December 31, 1999, there were approximately 657 shareholders of
record of the company's Common Stock.

        During the fiscal year ended December 31, 1999, the Company issued
securities using the exceptions available under the Securities Act of 1933
including unregistered sales made pursuant to Section 4(2) of the Securities Act
of 1933, as follows:

        The Company issued 34,393,524 shares of common stock for conversion of
$1,367,402 of notes payable and $5,104 of interest incurred on these notes.

        The Company issued 817,610 shares of common stock for services valued at
$65,000. And the Company issued 335,000 shares of common stock for professional
fees valued at $19,500.

        The Company issued 7,678,708 share of common stock for conversion of
debt valued at $170,448.

        The Company issued 18,510,000 shares of common stock for options
exercised valued $880,500

        The Company issued 1,275,000 shares of common stock for other
compensation valued at $63,750.

                                      -14-
<PAGE>

        During the first two Quarter of fiscal 2000 ending March 31, 2000 and
June 30, 2000, the Company issued securities using the exceptions available
under the Securities Act of 1933 including unregistered sales made pursuant to
Section 4(2) of the Securities Act of 1933, as follows:

        Quarter one ending March 31, 2000:

        The Company issued 3,010,808 shares of common stock for conversion of
debt valued at $134,000.

        The Company issued 4,565,000 shares of common stock for options
exercised valued at $656,500

        The Company issued 3,130,000 shares of common stock for other
compensation valued at $190,000.

        Quarter two ending June 31, 2000:

        The Company issued 500,000 shares of common stock for other compensation
valued at $50,000.


4.      Acquisitions
        ------------
        On June 1, 2000, the Company completed the acquisitions to acquire
Classic Care Pharmacy, a Los Angeles-based business to business pharmacy.
Through this acquisition, Kaire will be able to expand its business to business
and consumer customer base. The transaction resulted in the Company [aying
$4,100,000 consisting of $1,000,000 in cash and 15,500,000 shares of the
Company's common stock with a value of $3,100,000 for all the outstanding shares
of Classic Care Pharmacy.

        Additionally, the Company agrees to guarantee the shareholders of
Classic Care a $0.50 per share stock value of the Closing Shares, the Escrow
Shares and the Additional Shares. The stock price will be determined based on
the average of the low and high bid prices for Acquirer's common stock quoted
for the last ten trading days prior to three business days prior to the
effectiveness of a registration statement covering the subject shares. Here, the
Company agrees to subtract the stock price, based on a certain calculation from
$0.50 and, on the Effective Date of the Registration Statement, issue to Classic
Care's shareholders shares of the Company's common stock with a fair market
value equal to the aggregate amount of such shortfall (the "Make Whole Shares").
By way of illustration, if the Closing Shares, the Escrow Shares and the
Additional Shares total 20 million shares, but the fair market value as
determined on effective date is only $0.30 per share, then Acquirer would have
to issue to the Company Shareholders an amount of Make Whole Shares with a fair
market value equal to $4,000,000 (20 million X $0.20), or 13,333,333 shares ($4
million/$0.30). For the purposes of this report, diluted shares outstanding
include an additional 23,250,000 common shares to reflect potential dilution.

        The assets and liabilities acquired from Classic Care were as follows:

                                      -15-
<PAGE>

              Accounts receivable           $     320,803
              Inventory                           315,973
              Other current assets                 80,337
              Fixed assets                        238,485
              Intangibles                          52,386
              Goodwill                          3,790,794
              Account payable                    (390,886)
              Long term liabilities              (287,892)
                                                ---------

              Cost of net assets acquired       4,100,000


5.      Contingencies
        -------------

Federal Trade Commission Proceeding - Settled

    The Seattle Regional Office of the Federal Trade Commission had advised the
Company that it believed the Company's fat sequesterant product, which was
marketed by KCD, a former licensee, under the name "SeQuester," had been
improperly represented in advertising claims, and that the sequesterant product,
when previously marketed by the Company under the name "Lipitrol", also was
improperly represented in advertising claims. (Note, this product is no longer
marketed by Kaire Holdings). On June 16, 1996 the FTC filed a complaint be filed
against the licensee, the Company and certain individuals in connection with the
foregoing. Subsequently the Company and the FTC agreed upon a proposed
settlement in which the Company would consent to a permanent injunction
prohibiting it from making misrepresentations relating to weight loss or weight
reduction products or services, or with respect to tests or studies relating to
such programs or services. In addition, the Company would pay consumer redress
to the FTC in an aggregate amount of $35,000 over a period of twelve months. The
Company's Board of Directors voted to accept the proposal in March 1996, which
was formally approved by the FTC in June 1997. Final payment was made to the FTC
on April 16, 1998.

Siemens Credit Corporation - MRI Equipment Assigned to Third Party

       On or about February 19, 1992, Medical Funding of America ("MFA") leased
to Tri-County a Siemens Mobile Magneton Impact MRI System with a Van. On or
about June 24, 1992 Siemens and MFA entered into a loan and security agreement
in the amount of $2,019,496, which was, paid directly to Siemens Medical
Systems, Inc. On or about March 1, 1995 Siemens, MFA, Tri-County and Venus
Management (an Interactive Medical Technologies (Kaire Holdings) subsidiary
("Kaire")) entered into a transfer of interest agreement whereby Kaire gave its
corporate guaranty of all of Venus' obligations under this agreement. Venus and
MFA defaulted on the loan and on April 2, 1997 Siemens Credit Corporation filed
a civil action for the accelerated amount due plus costs. This action is still
pending. On or about October 9, 1997, a Transfer of Interest Agreement was drawn
up between Venus Management, Siemens Credit Corporation and Medical Management,
Inc. ("CMI") (NYSE: symbol CMI) whereby CMI would take over the lease. CMI took
possession of the MRI. All parties executed

                                      -16-
<PAGE>

the agreement except Siemens who continued to negotiate with CMI in an attempt
to get CMI to pay all of the arrearages owed Siemens. At present CMI and Siemens
are still negotiating over the terms of the agreement. It is the opinion of the
Company's management that its obligations under this agreement have been
assigned and that Siemens will not pursue this matter any further.


     Item 2.   Management's Discussion and Analysis or Plan of Operation

        The Company's former main business, E-Z Trac Division, was providing
non-radioactive diagnostic products and laboratory analysis services to private
and government research facilities, academic centers, and hospitals engaged in
studying the effects of experimental drugs and/or surgical procedures have on
regional blood flow. As previously disclosed, effective May 1, 2000, the Company
had entered into an agreement with Stason Labs of Irvine, whereby the laboratory
was transferred to Stason's Irvine facility for the purpose of providing better
service to existing customers plus to explore the possibilities of expanding the
laboratory services into new areas.

        E-Z Trac markets three products, two of which are designed for animal
blood flow studies, the E-Z Trac Ultraspheres and the NuFlow fluorescent
microspheres. The third product is a service the Company provides for its
clients which counts NuFlow fluorescent microspheres used in the blood flow
studies and measures regional blood flow under laboratory conditions.

        The E-Z Trac Ultraspheres are microspheres designed for small research
studies measuring regional blood flow. The NuFlow fluorescent microspheres are
designed to measure regional blood flow for both small or large regional blood
flow research studies using E-Z Trac's Investigative Partner Service ("IPS") to
analyze the studies samples. The Company markets microsphere products to
pharmaceutical companies, universities, hospitals and other academic centers
engaged in regional blood flow studies of experimental drugs or surgical
procedures.

        E-Z Trac Ultrasphere Microspheres

        The E-Z Trac Ultrasphere colored microspheres are the Company's original
product developed for regional blood flow studies. The raw materials necessary
for the production of the colored microspheres are available from numerous
sources. The microspheres are non-radioactive polystyrene spheres ranging from 3
to 200 microns in size. The Company treats and labels the microspheres in its
laboratory based upon a proprietary trade secret process. Eight non-radioactive
colored dyes are attached to the microspheres, giving them distinctive colors
when viewed and counted using a light microscope. The patented process also
involves a technology for separating the Ultrasphere from tissue and blood. The
Company also sells the reagents that are used in this patented process. The
Company's non-radioactive technique, has proven to be at least as accurate as
the radioactive microspheres technique, and eliminates the need and additional
cost required to dispose of radioactive waste. Other strengths offered by the
Ultraspheres are that they are stable over time and include eight different
colors that can be visualized simultaneously.

       Ultrasphere sales are made by the Company both directly to customers and
through two

                                      -17-
<PAGE>

  distributors in the U.S. and Japan. The distributors are Triton Technology and
  Primetec respectively. Customers include Bowman Gray School of Medicine, New
  York, Texas A&M, Cornell and Columbia Universities, Rhode Island Hospital,
  Hospital du Sacre Coeur de Montreal, University of New South Wales and others.

       Investigative Partner Services (IPS) with NuFlow Fluorescent Microspheres

       In connection with the development of NuFlow fluorescent microspheres,
  the Company established Investigator Partners Service ("IPS"). This service
  combines a national reference service with an automated laboratory analysis
  that includes counting the microspheres used in the blood flow studies. Here
  the Company offers a fast accurate method of measuring regional blood flow
  under laboratory conditions. The NuFlow fluorescent microspheres are counted
  using a customized Becton-Dickenson flow cytometer and the Company's own
  proprietary software. Besides achieving accurate results with this process,
  the Company has the capacity of analyzing approximately 800 samples per week.

       IPS typically receives its business from customers within the U.S.
  Depending on the order, the Company usually supplies its customer with a
  product kit that contains the necessary supplies, i.e. microspheres, test
  tubes, and instructions. Upon receiving the kit, the customer would run their
  experiment, placing the resulting tissue samples derived from the experiment
  into the tubes supplied from the kit and forward the kit to IPS for analysis.
  IPS typically returns the analysis results in seven to ten days. IPS sales are
  made both directly and through a distributor. The distributor is Triton
  Technology. Customers include SmithKline Beecham Pharmaceutical, Alliance
  Pharmaceutical, Case Western Reserve University and others. Further
  information can be found in Kaire Holdings above referenced website.

  YesRx.com

  YesRx is an internet-enabled drugstore that is focused on the distribution of
  pharmaceuticals, health, wellness and beauty products, as well as tens of
  thousands of pages of health-related information to targeted niche chronic
  care communities. The Company consists of 4 core business segments:

  YesRx.com: Internet-Enabled Pharmacy
  ---------

  YesRx.com is the internet segment of the Company. YesRx is a key component of
  the Company's overall pharmacy strategy as the Company intends to transition
  acquired customers from fax-based, walk-in and traditional mail-order ordering
  to internet-based ordering and account maintenance. YesRx is a fully
  integrated internet commerce catalogue of thousands of prescription and non-
  prescription products, durable medical equipment, tens of thousands of pages
  of health-related information, and comprehensive listing for related service
  providers.

  The Consumer Advocates Group: Understanding the Needs of Chronic Care Patients
  ----------------------------

  The Consumer Advocate Group is a program focused on the needs of specific
  chronic care communities.

                                      -18-
<PAGE>

  Some of these communities are: HIV/AIDS patients, Diabetics, Geriatric and
  Senior Citizens, and the Disabled. The Consumer Advocate Group has been
  charged to develop specific programs to meets the needs of these communities.
  Thus far, The Consumer Advocate Group has successfully implemented programs in
  the HIV/AIDS and Diabetic communities.

  YesRx International Licensing:  Brand Awareness and Deployment Internationally
  -----------------------------

     This division focuses on building the YesRx brand outside of the United
  States and in non-English speaking countries. Thus far, the YesRx.com website
  has been translated and is being used in various Spanish speaking communities.
  This business segment is currently developing a Chinese character version of
  YesRx for possible deployment in markets in Taiwan and China.

  Classic Care Pharmacy:  Assisted Living and B2B Solutions
  ---------------------

     On June 1, 2000, the Company completed the acquisition of Classic Care
  Pharmacy, a Los Angeles-based business to business pharmacy. Classic Care is a
  "high tech" assisted living facility pharmacy located in Los Angeles. Classic
  Care's houses some of the latest prescription fulfillment technologies from
  companies like Baxter HealthCare Systems and RNA Pharmacy Systems. These
  technologies allows this facility to fill up to 3,000 prescriptions per day
  for Classic Care's customer base which exceeds 3,000 beds.

   Results of Operations

   Three and Six Months Ended June 30, 1999 Compared to June 30, 2000

     For the three and six months ended June 30, 2000, revenues were
  approximately $727,785 and $788,844, an increase of $660,461 and $652,431
  respectively from the same periods in 1999. The increase was due to the
  acquisition of Classic Care Pharmacy. Revenue from laboratory operations For
  the three and six months ended June 30, 2000 were $14,148 and $73,806, a
  decrease of $53,193 and $62,623 respectively from the three and six months
  ended June 30, 1999. This decrease in lab revenue is a result of the
  laboratory operations being transferred to Stason Labs as of May 1, 2000.

     Gross profit for products and services was $262,870 and $292,861 for three
  and six months ended June 30, 2000, an increase of $208,999 and 177,155 over
  the same periods prior year. The increase was due to the acquisition of
  Classic Care Pharmacy.

     SG&A expense increased to $352,491 from $192,062 for the three months
  period ended June 30, 2000 and increased to $587,943 from $321,932 for the six
  months period ended June 30, 2000. The increase in SG&A was due to the
  following: 1) the acquisition of Classic Care accounted for $106,074 of the
  increase in both the three months and six months ended June 30, 2000 and 2)
  increases in the three and six month periods ended June 30, 2000 expenditures
  for Kaire Holdings's base businesses is related to the company's internet
  operations, i.e., consultants and internet access and hosting expenses.

                                      -19-
<PAGE>

     Interest expense for operations for the three and six month period ended
   June 30, 2000 was $0 compared to $17,351 for the comparable three month
   period prior year and $14,544 compared to $52,073 for the comparable six
   month period prior year. The decrease resulted from Conversion of significant
   amount of convertible notes into common stock during first and second
   quarters of 1999.

     No provision was made for Federal income tax since the Company has incurred
   significant net operating losses from inception. Through June 30, 2000, the
   Company incurred net operating losses for tax purposes of approximately
   $768,693. The net operating loss carry forward may be used to reduce taxable
   income through the year 2012. The Company's tax returns have not been audited
   by the Internal Revenue Service. The carry forward amounts may therefore be
   subject to audit and adjustment. As a result of the Tax Reform Act, the
   availability of net operating loss carry forwards can be deferred, reduced or
   eliminated under certain circumstances. Net operating losses in the State of
   California were not available for use during 1992 and the carry forward
   period has generally been reduced from fifteen years to five years beginning
   in 1993.


     Liquidity and Capital Resources
     -------------------------------

     The Company's revenues have been insufficient to cover acquisition costs,
   cost of revenues and operating expenses. Therefore, the Company has been
   dependent on private placements of common stock securities, bank debt, loans
   from private investors and the exercise of common stock warrants in order to
   sustain operations. In addition, there can be no assurances that private or
   other capital will continue to be available, or that revenues will increase
   to meet the Company's cash needs, or that a sufficient amount of the
   Company's common stock or other securities can or will be sold or that any
   common stock purchase options/warrants will be exercised to fund the
   operating needs of the Company.

        On June 30, 2000 the Company had assets of $5,523,455 compared to
   $160,000 on December 31, 1999, or an increase of $5,363,455 which is a result
   of the acquisition of Classic Care Pharmacy.. The Company had a total
   stockholders' equity of $4,015,142 on June 30, 2000 compared to a deficit of
   $586,426 on December 31, 1999, an increase in the equity of $4,601,568 which
   is also a result of the acquisition of Classic Care Pharmacy..

        As of June 30, 2000 the Company's working capital position increased
   $511,317 from a negative $586,426 at December 31, 1999 to a negative $75,109.
   The $511,317 increase was attributable to the following: 1) the Classic Care
   acquisition accounted for $309,983 of this increase and 2) an increase in
   Kaire Holdings cash of $121,994 and accounts receivable of $172,566 offset by
   an increase in accounts payable of $82,151 accounts for the remaining
   increase in working capital.

        In order to meet its current operating needs, the Company has reduced
   its cash requirements by transferring its E-Z division to Stason Labs. The
   Company feels that further expense reductions plus the added cash generated
   by the Classic Care division should provide enough cash to sustain the
   operations of the business in short run.

     Year 2000 Issue

                                      -20-
<PAGE>

      The Company experienced no disruption in business to customers or vendors
   or had a material adverse effect on the company's business, financial
   condition or results of operations related to the year 2000.

                                      -21-
<PAGE>

                          PART II.  OTHER INFORMATION
                          ---------------------------

   Item 1.  Legal Proceedings

   Federal Trade Commission Proceeding - Settled

      The Seattle Regional Office of the Federal Trade Commission had advised
   the Company that it believed the Company's fat sequesterant product, which
   was marketed by KCD, a former licensee, under the name "SeQuester," had been
   improperly represented in advertising claims, and that the sequesterant
   product, when previously marketed by the Company under the name "Lipitrol",
   also was improperly represented in advertising claims. (Note, this product is
   no longer marketed by Kaire Holdings). On June 16, 1996 the FTC filed a
   complaint be filed against the licensee, the Company and certain individuals
   in connection with the foregoing. Subsequently the Company and the FTC agreed
   upon a proposed settlement in which the Company would consent to a permanent
   injunction prohibiting it from making misrepresentations relating to weight
   loss or weight reduction products or services, or with respect to tests or
   studies relating to such programs or services. In addition, the Company would
   pay consumer redress to the FTC in an aggregate amount of $35,000 over a
   period of twelve months. The Company's Board of Directors voted to accept the
   proposal in March 1996, which was formally approved by the FTC in June 1997.
   Final payment was made to the FTC on April 16, 1998.

   Siemens Credit Corporation  - MRI Equipment Assigned to Third Party

        On or about February 19, 1992, Medical Funding of America ("MFA") leased
   to Tri-County a Siemens Mobile Magneton Impact MRI System with a Van. On or
   about June 24, 1992 Siemens and MFA entered into a loan and security
   agreement in the amount of $2,019,496, which was, paid directly to Siemens
   Medical Systems, Inc. On or about March 1, 1995 Siemens, MFA, Tri-County and
   Venus Management (an Interactive Medical Technologies (Kaire Holdings)
   subsidiary ("Kaire")) entered into a transfer of interest agreement whereby
   Kaire gave its corporate guaranty of all of Venus' obligations under this
   agreement. Venus and MFA defaulted on the loan and on April 2, 1997 Siemens
   Credit Corporation filed a civil action for the accelerated amount due plus
   costs. This action is still pending. On or about October 9, 1997, a Transfer
   of Interest Agreement was drawn up between Venus Management, Siemens Credit
   Corporation and Medical Management, Inc. ("CMI") (NYSE: symbol CMI) whereby
   CMI would take over the lease. CMI took possession of the MRI. All parties
   executed the agreement except Siemens who continued to negotiate with CMI in
   an attempt to get CMI to pay all of the arrearages owed Siemens. At present
   CMI and Siemens are still negotiating over the terms of the agreement. It is
   the opinion of the Company's management that its obligations under this
   agreement have been assigned and that Siemens will not pursue this matter any
   further.

      Item 4.  Submission of Matters of a Vote to Security Holders

      On or about October 1, 1997, a proposal to increase the number of
   authorized shares to 400,000,000

                                      -22-
<PAGE>

   for the purpose to provide for the merger with Kaire International, Inc. was
   voted upon and authorized by a majority of Kaire Holdings, Inc. shareholders.

      On or about January 30, 1998, a proposal to 1) reverse split the Company's
   common stock up to and not to exceed a reverse ratio of seventy-five to one,
   2) amend the Company's Articles of Incorporation changing the Company name to
   Kaire Holdings Incorporated and 3) changing the Company's NASDAQ symbol to
   KHI was voted and authorized by a majority of Kaire Holdings, Inc.
   shareholders. These changes became effective on February 19, 1998.

   Item 6.    Exhibits and Reports on Form 8-K:

         (a)  Exhibits

              27  Financial Data Schedule

         (b)  The Company filed the following Reports on form 8-K:

              1. Form 8-K dated February 19, 1998 reporting a change in the
         Company's independent account, a name change, a seventy - five to one
         reverse common stock split, and the signing of an agreement to purchase
         thirty - five percent in a Singapore company and its Mainland China
         multi level marketing subsidiary.

              2. Form 8-K dated April 8, 1999 reporting a change in the
         Company's independent account and the resignation of Peter Benz as the
         Company's President and Board member.

              3. Form 8-K June 22, 2000 reporting the acquisition of Classic
         Care Pharmacy.

                                      -23-
<PAGE>

                                  SIGNATURES
                                  ----------

        Pursuant to the requirements of Section 13 or 15(d) of the Securities
   Exchange Act of 1934, the Registrant has duly caused this report to be signed
   on its behalf by the undersigned, thereunto duly authorized.

                     KAIRE HOLDINGS INCORPORATED.
                    -----------------------------
                       (Registrant)



   Date: September 6, 2000         By: /s/ Steven R. Westlund
                                       ----------------------
                                       Steven Westlund
                                       (Chief Executive Officer)


   Date: September 6, 2000         By: /s/ OWEN M. NACCARATO
                                       ---------------------
                                       Owen M. Naccarato
                                       (Chief Financial Officer)


   Date: September 6, 2000         By: /s/ Asher Gottesman
                                       --------------------
                                       Asher Gottesman

                                      -24-